Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Balversa (erdafitinib)
Pharma
J&J's Balversa gets mixed label update in FDA approval conversion
The way J&J approached the full approval—and the way the FDA ruled—tell a cautionary tale about the FDA's close attention to data.
Angus Liu
Jan 22, 2024 11:12am
ASCO: J&J's Balversa wins out over chemo in bladder cancer study
Jun 5, 2023 2:39pm
ASCO: J&J touts Balversa's pan-tumor power, plots FDA talks
May 26, 2022 5:00pm